Meril Lifesciences brought together some of India’s most distinguished oncology experts at OncoXchange, a panel discussion held at Meril Academy, Aloft Hotel, Aerocity, New Delhi. The event aimed to catalyse progressive dialogue around the future of cancer care in India.
The event witnessed the presence of 26 surgical consultants and directors from the medical community across the Indian oncology community, representing a wide spectrum of expertise and experience. Leading the discussion on the multidisciplinary approach to cancer treatment were panellists Dr Naveen Sanchety, Dr Vedant Kabra, Dr Azhar Perwaiz, and Dr Ashish Goel, with moderation by Dr Harit Chaturvedi and Dr Pradeep Jain.
Dr Harit Chaturvedi remarked, “The future of oncology in India lies in integrating AI seamlessly into clinical workflows, ensuring the highest quality of patient data, prioritising ethical practices, equipping healthcare professionals with digital skills and keeping patient-centricity at the core. Our vision for Indian oncology embraces a multidisciplinary approach to cancer treatment, fostering innovation beyond surgery, and recognising the expanding role of Indian MNCs. By addressing gaps in treatment options and leveraging newer technologies for precise treatment planning, we aim to put Indian oncology firmly ontheworldmap.”
In another insightful discussion centred on innovation beyond surgery and the expanding role of Indian MNCs, key perspectives were shared by Dr Asit Arora, Dr Rudra Prasad Acharya, Dr Saleem Naik, and Nitin Thakur. This session was steered by moderators Dr Chintamani and Dr Geeta Kadayaprath.
“Innovation in cancer care is no longer confined to the operating room — it extends to technology, training, and the global leadership Indian MNCs are beginning to shape. The future lies in thinking beyond surgery to create a holistic ecosystem of solutions,” said Dr Chintamani.
The forum was further enriched by valuable perspectives on “Putting Indian Oncology on the World Map” from Dr Saumitra Rawat, Dr Mudit Agarwal, Dr Nikhil Agrawal, Dr Arvind Kumar, and Dr S.V.S. Deo, making OncoXchange a truly collaborative and insightful gathering.
Commenting on Indian oncology, Dr S.V.S. Deo said, “Indian oncology has the expertise, innovation, and collaborative spirit to make a global impact. Platforms like OncoXchange are vital in uniting our brightest minds to put India firmly on the world map of cancer care. Our aim is to transform patient care and bring change in the Indian oncology ecosystem.”
“Cancer cases are rising in India, from GI to thoracic, and we at Meril remain committed to transforming care through innovation, training, and collaboration. We aim to foster a shared vision for innovation, collaboration, and patient-centric treatment strategies,” said Nitin Thakur, Business Head – Sales and Marketing, Meril Lifesciences
Vivek Shah, CEO, Meril Lifesciences, said, “Our flagship platform, OncoXchange, is designed to transform cancer treatment by bringing together the brightest minds to co-create patient-centric, integrated solutions for the future of oncology care.”